每年出版 4 期
ISSN 打印: 0893-9675
ISSN 在线: 2162-6448
Indexed in
HDAC6-Dependent Functions in Tumor Cells: Crossroad with the MAPK Pathways
Get access
摘要
Histone deacetylase 6 (HDAC6) is emerging as a novel therapeutic target in cancer treatment. HDAC6 plays an important role in cell migration, cell transformation, and DNA damage response. Our and others' studies have linked HDAC6's functions and HDAC6's regulation to the mitogen-activated protein kinase (MAPK) pathways. In particular, HDAC6's activity has been found to be regulated by EGF-EGFR-Ras-Raf-MEK-ERK signaling. Inversely, HDAC6 has been reported to modulate the functions of EGFR and Ras. In this review, we summarize the literature on HDAC6 and MAPK pathways, and emphasize the interaction between HDAC6 and the ERK-MAPK signaling cascade.
-
Duvic Madeleine, Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma, Dermatologic Clinics, 33, 4, 2015. Crossref
-
Goracci Laura, Deschamps Nathalie, Randazzo Giuseppe Marco, Petit Charlotte, Dos Santos Passos Carolina, Carrupt Pierre-Alain, Simões-Pires Claudia, Nurisso Alessandra, A Rational Approach for the Identification of Non-Hydroxamate HDAC6-Selective Inhibitors, Scientific Reports, 6, 1, 2016. Crossref
-
Bao Haidong, Liu Peng, Jiang Ke, Zhang Xianbin, Xie Long, Wang Zhongyu, Gong Peng, Huaier polysaccharide induces apoptosis in hepatocellular carcinoma cells through p38 MAPK, Oncology Letters, 12, 2, 2016. Crossref
-
Tsimberidou Apostolia M., Beer Philip A., Cartwright Carrie A., Haymaker Cara, Vo Henry H., Kiany Simin, Cecil Alexander R.L., Dow James, Haque Kemal, Silva Franck A., Coe Lucy, Berryman Helen, Bone Elisabeth A., Nogueras-Gonzalez Graciela M., Vining David, McElwaine-Johnn Hilary, Wistuba Ignacio I., Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors, Clinical Cancer Research, 27, 13, 2021. Crossref